Inclusion Criteria:~* Male or female patients aged ≥ 60 years.~* Patient with a diagnosis of probable AD~*
Progressive decline in cognition for more than six months which story is documented in patient medical
records~* A Mini-Mental State Examination (MMSE) score of 20-26~* With a minimum of educational background~*
NaÃ¯ve to anti-dementia treatment~* MRI assessment which corroborates the clinical diagnosis (hippocampal
atrophy) and excludes other potential causes of dementia especially cerebrovascular lesions~* If available,
Cerebral Spinal Fluid (CSF) classical biomarkers should be at levels which corroborate the clinical diagnosis~*
Ambulatory patient living at home with a caregiver available and living in the same household or interacting
with the patient daily and available if necessary to ensure administration of the investigational product~*
Absence of major or severe depressive disease~* Patient with a willingness to participate in this study and who
have signed an informed consent form~
